Starting in the late 1960s and early 1970s, a group of aspiring young scientists gathered at the Salk Institute for Biological Studies in La Jolla, California. This group of trainees and junior faculty included Steve Heinemann, Rudolf Jaenisch, Inder Verma, Tony Hunter, the late Wylie Vale, and, soon thereafter, Ron Evans. In the years to come, this erstwhile group of young mavericks went on to define science not only at the Salk but, in some sense, for the entire world. In neuroscience, the defining force was Stephen F. Heinemann, who passed away on August 6, 2014, of kidney failure. For several years, Steve was elected the head of the Faculty at the Salk, and his beloved and yet straightforward, honest character served him well in bringing together diverse personalities, approaches, and interests.
Steve was best known for his science. He and his colleagues changed the way we view neurotransmitter receptors in the brain, thus influencing the future study of learning, memory, and disease. He, more than anyone else, taught us the power of cloning these receptors, characterizing their properties, and determining how mutations influence their function. Prior to Steve's work, we knew that excitatory neurotransmitters mediated these processes via synaptic transmission, but their receptors remained contentious, usually named for the ligand with the highest affinity. Steve and his colleagues, particularly Jim Patrick, and also Jim Boulter, Michael Hollmann, and others, changed all this-cloning various subunits of the neuronal receptors for both acetylcholine (nicotine) and glutamate, the two major excitatory transmitters. Steve and his group went on to sort out how the various subunits and their constituent amino acids accounted for many of the well-known properties of these neurotransmitter receptors. This toolbox allowed the field to study in depth the molecular underpinnings of normal processes such as learning and memory, as well as many neurological diseases. These maladies range from myasthenia gravis to traumatic brain injury to Huntington's disease to Alzheimer's disease. In recent years, it has become clear that aberrant function of these receptors also contributes to neuropsychiatric disorders. Moreover, his discovery of these receptors gave pharmaceutical companies new targets to explore in order to treat these diseases. Upon his death, the Salk Institute wrote, ''Groundbreaking findings from his laboratory supported the idea that many diseases of the brain result from deficits in communication between nerve cells, and he was widely considered one of the world's most accomplished neuroscientists.'' Born in 1939 to Robert B. Heinemann and Christel Fuchs, Steve lived in Cambridge, Massachusetts during his early years and attended Buckingham Browne & Nichols secondary school. This must have been a very exciting time in Cambridge. Rumor had it that Steve's first chemistry set came from his uncle, Klaus Fuchs, a theoretical physicist who had worked on the Manhattan project under Hans Bethe during World War II but later confessed to being a communist spy. Steve met his wife of 54 years, Ann Reischauer Heinemann, in Cambridge, and her side of the family was no less brilliant and interesting than his. Ann's father, Edwin Reischauer, a renowned Harvard professor of East Asian studies, served as US ambassador to Japan in the 1960s. Reischauer was effective in large measure because his second wife, Haru Matsukata, granddaughter of a prince and former prime minister of Japan, was a revered symbol of Japanese culture and mores. She was introduced to Edwin Reischauer by none other than the novelist James Michener, and together the Reischauers eased tensions between Japan and the US after World War II. And Ann Heinemann, like her father Edwin and her stepmother Haru, did not fall far from the tree-brilliant in her own right, with tremendous insight into human character and concern for the welfare of humankind. Ann was very influential on Steve and his unfaltering values for humanity, fairness, and justice.
Steve earned his undergraduate degree from Caltech in 1962 and a PhD in biochemistry under advisor Matt Meselson at Harvard in 1967 and then performed postdoctoral work at MIT and Stanford. During this period, Steve was also known for his prowess as a baseball pitcher at Caltech (of all places). With his wry sense of wit, Steve recounted that the Caltech coach once came to the mound to take him out of the game after getting behind 12 to 0 in the third inning but only to preserve his arm so he could start the second game of the doubleheader to be played later that same afternoon! After joining the Salk Institute in 1970, at the behest of nonresident fellow and advisor Stephen Kuffler from Harvard, Heinemann founded the Molecular Neurobiology Laboratory, ''a program that by the late 1980s was ranked number one in the world,'' according to Salk Institute sources. During those early years, Steve worked on nerve-muscle preparations and snake-derived nicotinic toxins with Dave Schubert, John Henry Steinbach, Jim Patrick, and others. Unexpectedly, while making antibodies to acetylcholine receptors isolated from the eel electric organ, Jim Patrick and John Lindstrom noticed that their rabbits developed a flaccid paralysis and abnormal electromyograms. These symptoms and signs were dramatically ameliorated by acetylcholinesterase inhibitors, characteristic of human myasthenia gravis. Steve and colleagues took the next step and demonstrated that human
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Between 1982 and 1991, Steve and colleagues were the first to clone and characterize subunits of the neuronal nicotinic (nAChR) and glutamatergic receptor families. In 1991, Shigetada Nakanishi (in Japan) and his colleagues cloned and characterized the first subunit of the N-methyl-D-aspartate (NMDA) glutamate receptor subtype, complementing these studies. Characterization in the Heinemann Lab of cytisine as a partial agonist of the a4/b2 nAChR that ostensibly mediates the addictive properties of nicotine was the impetus for the synthesis of varenicline (Chantix), which is prescribed for nicotine addiction and smoking cessation. With their molecular expertise, Steve Heinemann's group and Peter Seeburg's group (in Germany) independently characterized not only a number of glutamate receptor subunits but also RNA editing of specific subunits (e.g., GluA2), which accounted for their permeability to calcium and hence their role in both neuroplasticity and neurodegeneration. These findings have possible implications for both global cerebral ischemia and amyotrophic lateral sclerosis. In 1989, Steve was joined at the Salk Institute by one of us, Chuck Stevens, who moved from Yale, and had a contiguous laboratory to Steve's.
More recently, Steve's receptor discoveries led to systems neurobiological approaches with experiments using gene knockouts to discern the importance of these receptors in neural networks and behavior. Additional studies with colleagues showed that aberrant activation of both nicotinic acetylcholine and glutamate receptors in Alzheimer's disease may mediate the neurotoxic effect of b-amyloid peptide. Specifically, b-amyloid engagement of a7 nAChRs on astrocytes was found to trigger astrocytic glutamate release. In turn, glutamate activated extrasynaptic NMDA-type glutamate receptors on nearby neurons, stimulating a series of deleterious molecular pathways that contribute to synaptic damage, the underlying defect accounting for memory loss in Alzheimer's. This work has provided the impetus to develop drugs for Alzheimer's disease using these receptors as targets.
During his lifetime, Steve received numerous awards and honors and was a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Steve was elected President of the Society for Neuroscience and served that organization faithfully, meeting tirelessly with congressmen and others to advance the cause of neuroscientists and increase their level of funding.
Steve's awards include the BristolMyers Squibb Distinguished Achievement in Neuroscience Research Award, the McKnight Award for Research, and in 2010, the Julius Axelrod Prize for exceptional achievements in neuropharmacology and mentoring young scientists. Along these lines, when he passed, there was an outpouring of emails from former students and postdoctoral fellows praising his compassion and mentoring skills.
In addition to his wife, Ann, Steve is survived by their five children, his four sisters, and twelve grandchildren, all of whom gave him great joy, especially when they visited the family farm in Vermont during the summers.
Finally, and perhaps most importantly, we come to Steve Heinemann's character. Steve had the best moral compass of anyone, scientist or layperson, we have ever known. He had the courage not only to tell a good story but one that always took the correct ethical stand no matter what the consequences to him personally. He was resolute in standing up for the right course of action. He believed in sharing scientific reagents such as the receptor clones generated in his laboratory with other scientists shortly after their publication and felt other scientists should do likewise. Steve was a voice of reason; he felt that scientific principles and fairness of action, not politics, should pave the pathway forward for scientific endeavors. Whether you agreed or disagreed with him, one has to respect the values, achievements, humility, and humanity of Steve Heinemann. Quite a man, and on that final note, we can all agree.
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